Strongbridge Biopharma (Strongbridge Biopharma) Gross Profit : $32.99 Mil (TTM As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Gross Profit?

Strongbridge Biopharma's gross profit for the three months ended in Jun. 2021 was $9.58 Mil. Strongbridge Biopharma's gross profit for the trailing twelve months (TTM) ended in Jun. 2021 was $32.99 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Strongbridge Biopharma's gross profit for the three months ended in Jun. 2021 was $9.58 Mil. Strongbridge Biopharma's Revenue for the three months ended in Jun. 2021 was $10.04 Mil. Therefore, Strongbridge Biopharma's Gross Margin % for the quarter that ended in Jun. 2021 was 95.35%.

Strongbridge Biopharma had a gross margin of 95.35% for the quarter that ended in Jun. 2021 => Durable competitive advantage

During the past 8 years, the highest Gross Margin % of Strongbridge Biopharma was 95.02%. The lowest was 77.89%. And the median was 80.68%.

Strongbridge Biopharma Gross Profit Historical Data

The historical data trend for Strongbridge Biopharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma Gross Profit Chart

Strongbridge Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Gross Profit

Get a 7-Day Free Trial

5.56

14.04

17.89

28.52

Strongbridge Biopharma Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Gross Profit	Get a 7-Day Free Trial															7.37	7.66	7.78	7.97	9.58

Competitive Comparison of Strongbridge Biopharma's Gross Profit

For the Biotechnology subindustry, Strongbridge Biopharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strongbridge Biopharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Gross Profit falls into.

Strongbridge Biopharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Strongbridge Biopharma's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )	=	Revenue	-	Cost of Goods Sold
	=	30.731	-	2.212
	=	28.52

Strongbridge Biopharma's Gross Profit for the quarter that ended in Jun. 2021 is calculated as

Gross Profit (Q: Jun. 2021 )	=	Revenue	-	Cost of Goods Sold
	=	10.042	-	0.467
	=	9.58

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.99 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Strongbridge Biopharma's Gross Margin % for the quarter that ended in Jun. 2021 is calculated as

Gross Margin % (Q: Jun. 2021 )	=	Gross Profit (Q: Jun. 2021 )	/	Revenue (Q: Jun. 2021 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	9.58	/	10.042
	=	95.35 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Strongbridge Biopharma (NAS:SBBP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Strongbridge Biopharma had a gross margin of 95.35% for the quarter that ended in Jun. 2021 => Durable competitive advantage

Strongbridge Biopharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053

Website

http://www.strongbridgebio.com

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Executives

David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c.	10 percent owner	C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner	10 percent owner	C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp	10 percent owner	731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen	director	60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger	director	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long	officer: Chief Legal Officer	C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen	officer: Chief Medical Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit	officer: Chief Commercial Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz	officer: Chief Financial Officer	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender	officer: Chief Operating Officer	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380